Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist

https://doi.org/10.1016/0014-2999(87)90772-2Get rights and content

Abstract

CGS 12066B is a novel pyrroloquinoxaline with selectivity for the serotonin-1B (5HT1B) recognition site as assessed by binding, biochemical and electrophysiological studies. The compound had an IC50 value of 51 nM at the 5HT1B recognition site as determined using the binding of [3H]5HT in the presence of 1 μM spiperone. At the 5HT1A receptor the compound had an IC50 value of 876 nM, providing a 5HT1A/5HT1B ratio of 17 in contrast to the putative 5HT1B selective agent trifluoromethylphenylpiperazine (TFMPP) which had a corresponding ratio of 3.6. The compound had minimal affinity for α1-, α2- and β-adrenoceptors and for dopamine D-1 and D-2 receptors. CGS 12066B, in contrast to TFMPP, which was inactive, was found to inhibit dorsal raphe cell firing with an ED50 value of 358 nmol/kg i.v. The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg. CGS 12066B was also effective in decreasing rat brain 5-HTP concentrations and inhibiting in vitro 5HT release. The data obtained indicate that CGS 12066B is a reasonably active 5HT1B site agonist, which due to its selectivity as compared to compounds such as TFMPP, will be a useful tool for evaluating the physiological role of such receptors in the mammalian CNS.

References (44)

  • D.N. Middlemiss

    Functional correlates of the subtypes of the 5-HT recognition site

    Trends Pharmacol. Sci.

    (1986)
  • D.N. Middlemiss et al.

    8-Hydroxy-2-(di-propylamino)tetralin discriminates between subtypes of the 5-HT1 recognition site

    European J. Pharmacol.

    (1983)
  • S.J. Peroutka

    Selective labeling of 5HT1A and 5HT1B binding sites in bovine brain

    Brain Res.

    (1985)
  • D.J. Pettibone et al.

    Serotonin-releasing effects of substituted piperazines in vitro

    Biochem. Pharmacol.

    (1984)
  • J.R. Schlegel et al.

    Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT)

    Biochem. Pharmacol.

    (1986)
  • P. Seeman et al.

    Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors

    European J. Pharmacol.

    (1979)
  • L. Semerdjian-Rouquier et al.

    Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reverse-phase high-performance liquid chromatography with electrochemical detection

    J. Chromatogr.

    (1981)
  • J. Traber et al.

    Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821

    Brain Res. Bull.

    (1984)
  • M. Williams et al.

    Anxiolytics, anticonvulsants and sedative hypnotics

    Ann. Rep. Med. Chem.

    (1986)
  • G. Battaglia et al.

    pH-dependent modulation of agonist interactions with [3H]ketanserin-labelled S2 serotonin receptor

    Life Sci.

    (1982)
  • A. Braunwalder et al.

    Characterization of [3H]clonidine binding to two sites in calf brain membranes

    J. Neurochem.

    (1981)
  • D.B. Bylund et al.

    Beta adrenergic receptor binding in membrane preparations from mammalian brain

    Mol. Pharmacol.

    (1976)
  • Cited by (151)

    • Route to pyrrolo[1,2-a]quinoxalines via a furan ring opening-pyrrole ring closure sequence

      2020, Tetrahedron Letters
      Citation Excerpt :

      Pyrrolo[1,2-a]quinoxalines and their (partially) hydrogenated analogues belong to an important family of heterocycles found in various natural compounds, including those possessing a broad diversity of biological activities. For example, quinoxaline I was recently isolated from Piper nigrum L. and Piper longum L. [1]; compound II is an arginine vasopressin antagonist with selectivity for the V2 receptor [2]; carboxylic acid III and related compounds possess anti-allergic activity [3]; PPQ-102 is an inhibitor of the cystic fibrosis transmembrane conductance regulator [4]; CGS 12066B is a potent and selective agonist for the 5-HT1B receptor [5]; quinoxaline IV is an inhibitor of PARP-1 [6]. The diverse biological activities of pyrrolo[1,2-a]quinoxalines open promising possibilities for drug discovery and development based on this heterocyclic motif (Fig. 1).

    • The role of peripheral 5-HT<inf>1A</inf>, 5-HT<inf>1B</inf>, 5-HT<inf>1D</inf>, 5-HT<inf>1E</inf> and 5-HT<inf>1F</inf> serotonergic receptors in the reduction of nociception in rats

      2010, Neuroscience
      Citation Excerpt :

      The serotonergic drugs tested were selected based on relevant receptor selectivity and efficacy (see Table 1). These included: (i) 5-HT1 receptor agonists such as R(+)-UH-301 (5-HT1A, Björk et al., 1992), CGS-12066A (5-HT1B, Neale et al., 1987), GR46611 (5-HT1B/1D, Barf et al., 1996; O'Neill and Sanger, 1999), BRL54443 (5-HT1E/5-HT1F, Brown et al., 1998) and LY344864 (5-HT1F, Phebus et al., 1997); and (ii) selective 5-HT1 receptor antagonists such as WAY-100635 (5-HT1A, Forster et al., 1995; Fletcher et al., 1996), GR55562 (5-HT1B/1D, Lamothe et al., 1997; Filip et al., 2001), SB224289 (5-HT1B, Selkirk et al., 1998; De Vries et al., 1998) and BRL15572 (5-HT1D antagonist, Price et al., 1997). Since currently there are no selective antagonists for 5-HT1E and 5-HT1F receptors, methiothepin was used based on its moderate affinity for these receptors (see Table 1; Adham et al., 1992; Zgombick et al., 1992).

    View all citing articles on Scopus
    View full text